Betalok is a beta1-blocker, which has antianginal, antiarrhythmic and hypotensive actions.
Release form and composition
Betalok made in the form of tablets and solution.
1 tablet Betalok contains 50 or 100 mg of metoprolol tartrate, as well as auxiliary components: lactose monohydrate, microcrystalline cellulose, colloidal silica, magnesium stearate, povidone, carboxymethyl starch sodium.
The solution for intravenous administration of Betaloc contains 5 mg of metoprolol tartrate in 1 ampoule, as well as excipients: water for injection, sodium chloride.
Indications for use
According to the instructions, Betalok is shown under the following conditions:
- Angina pectoris;
- Hyperthyroidism (as part of complex treatment);
- Arterial hypertension to reduce blood pressure and minimize the risk of coronary and cardiovascular death;
- Heart rhythm disorders, including supraventricular tachycardia;
- Functional disorders of the heart, accompanied by heart palpitations.
Also shown Betalok for the prevention of migraine attacks and as part of complex therapy after myocardial infarction.
According to the instructions, Betalok is contraindicated in the following cases:
- Heart failure in the decompensation stage;
- Atrioventricular block 2 and 3 degrees;
- Pronounced disorders of the peripheral blood system;
- Cardiogenic shock;
- Sick sinus syndrome;
- Acute myocardial infarction (heart rate less than 45 beats per minute, blood pressure less than 100 mm Hg., PQ interval more than 0.24 seconds);
- Age up to 18 years;
- Serious peripheral vascular diseases, accompanied by the risk of gangrene;
- Hypersensitivity to metoprolol or auxiliary components of the drug;
- Long-term or intermittent therapy with inotropic drugs acting on beta-adrenoreceptors.
In the application of Betalok should be careful when:
- Atrioventricular block 1 degree;
- Chronic obstructive pulmonary disease (emphysema, bronchial asthma, chronic obstructive bronchitis);
- Printsmetal angina pectoris;
- Severe kidney failure.
Dosing and Administration
Betalok tablets are indicated for internal use both on an empty stomach and with food.
When arterial hypertension, angina pectoris, heart rhythm disturbances, for the prevention of migraine attacks, 100-200 mg of Betalok is administered once or in the morning and evening. If necessary, concomitant therapy with another antianginal drug is added.
As a maintenance therapy after myocardial infarction, Betalok is prescribed in a dose of 200 mg divided into two doses.
When functional disorders of the heart, accompanied by rapid heartbeat, prescribed Betalok at a dose of 100 mg once a day, preferably in the morning.
In hyperthyroidism, 150-200 mg of Betalok is prescribed, divided into 3-4 doses.
The solution Betalok for intravenous administration is prescribed in a dose of 5 ml at a rate of 1-2 ml per minute. It is allowed to re-use Betalok after 5 minutes to achieve the optimal therapeutic effect. As a rule, the total dosage of Betalok is 10-15 ml.
In case of overdose, the following symptoms may occur:
- A pronounced decrease in blood pressure;
- Heart failure;
- Sinus bradycardia;
- Nausea and vomiting;
- Atrioventricular block;
- Cardiogenic shock;
- Heart failure.
When the above symptoms appear, the patient should do a gastric lavage and take the adsorbents. With a marked reduction in blood pressure and the threat of heart failure, it is recommended that beta1-adrenomimetic be administered.
As a rule, the use of Betalok in recommended doses by patients is well tolerated. Side effects are unexpressed and reversible:
- Cardiovascular system: heartbeat, bradycardia, postural disorders, cooling of the limbs;
- Central nervous system: dizziness, fatigue, headache, anxiety, increased nervous irritability, sexual dysfunction;
- Gastrointestinal: pain in the abdomen, nausea, abnormal stool, dry mouth, vomiting;
- Liver: abnormal liver function, hepatitis;
- Respiratory: bronchospasm, shortness of breath, rhinitis;
- Skin: hyperhidrosis, urticaria, alopecia, photosensitivity, exacerbation of psoriasis;
- Sense organs: conjunctivitis, visual disturbances, tinnitus, taste disturbances, irritation or dry eyes.
Betalok should not be combined with intravenous administration of slow calcium channel blockers (verapamil). Patients with chronic heart failure in the stage of decompensation should use a compensation stage before using Betalok.
If, as a result of treatment with Betaloc, the patient developed bradycardia, the dosage of the drug should be reduced or phased out.
It is not recommended to carry out a sharp cancellation of Betalok. The dosage should be reduced gradually. In most patients, the optimal time to discontinue the drug is 2 weeks. The dose is reduced gradually, in several doses, until reaching 25 mg of the drug per day. In patients with coronary heart disease, patients should abolish Betalok under the careful supervision of the attending physician.
Since Betalok can cause dizziness and general weakness of the body, it is not recommended during therapy to manage potentially dangerous mechanisms requiring increased concentration of attention.
Structural analogues of the drug Betalok are the following drugs:
- Betalok ZOK;
Terms and conditions of storage
According to the instructions, Betalok should be stored in a cool place out of reach of children. Shelf life - 5 years.